You are here
iX Biopharma granted patent in Canada for WaferiX
HOMEGROWN specialty pharmaceutical company iX Biopharma has been granted a patent in Canada for its WaferiX drug delivery technology.
The grant of the Canadian patent expires on Oct 26, 2030.
Canada has a potential market size of C$515 million and C$97 million for opioids and sleep aids, the company said, citing the Patented Medicine Prices Review Board of Canada and Euromonitor, respectively.
The group has also been granted a patent in South Korea this year, while counterpart patents were granted in Australia, Indonesia, Japan, Malaysia, New Zealand and Singapore prior to that.
According to its website, WaferiX technology consists of a small wafer which uses the freeze drying process. The wafer is placed under the tongue, where it dissolves within a minute, releasing the active compounds.